NVAX

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Novavax (NVAX - Research Report), with a price target of $74.00. The company's shares opened today at $16.97.According to TipRanks, Mamtani is an analyst with an average return of -30.9% and a 18.80% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Novavax, Altimmune, and Agenus.The word on The Street in general, suggests a Hold analyst consensus rating for Novavax with a $54.25 average price target.See the top stocks recommended by analysts >>The company has a one-year high of $236.50 and a one-year low of $16.00.
https://www.tipranks.com/news/blurbs/novavax-nvax-receives-a-buy-from-b-riley-financial?utm_source=advfn.com&utm_medium=referral